scholarly journals Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease

Cells ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 2978
Author(s):  
Stanislav Kotlyarov ◽  
Aleksei Bulgakov
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lipid Metabolism ◽  
Liver Disease ◽  
Fatty Liver ◽  
Pulmonary Disease ◽  
Fatty Liver Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Alcoholic Fatty Liver ◽  
Lipid Metabolism Disorders

Non-alcoholic fatty liver disease (NAFLD) is currently among the most common liver diseases. Unfavorable data on the epidemiology of metabolic syndrome and obesity have increased the attention of clinicians and researchers to the problem of NAFLD. The research results allow us to emphasize the systemicity and multifactoriality of the pathogenesis of liver parenchyma lesion. At the same time, many aspects of its classification, etiology, and pathogenesis remain controversial. Local and systemic metabolic disorders are also a part of the pathogenesis of chronic obstructive pulmonary disease and can influence its course. The present article analyzes the metabolic pathways mediating the links of impaired lipid metabolism in NAFLD and chronic obstructive pulmonary disease (COPD). Free fatty acids, cholesterol, and ceramides are involved in key metabolic and inflammatory pathways underlying the pathogenesis of both diseases. Moreover, inflammation and lipid metabolism demonstrate close links in the comorbid course of NAFLD and COPD.

scholarly journals FREQUENCY OF EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AS ONE OF THE FACTORS OF PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE

InterConf ◽  
2021 ◽  
pp. 262-266
Author(s):  
Мaria Derbak ◽  
Iryna Khramtsova
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Liver Disease ◽  
Fatty Liver ◽  
Pulmonary Disease ◽  
Fatty Liver Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease ◽  
Severe Grade

This article presents the results of studies obtained by observing patients with non-alcoholic fatty liver disease (NAFLD) on the background of chronic obstructive pulmonary disease (COPD). As a result of the analysis it was found that the frequency of exacerbations of COPD with hospitalization in overweight patients in the presence of NAFLD leads to increased imbalance of adipose tissue hormones in the form of decreased adiponectin and increased leptin, and correlates with impaired lipid metabolism and severe grade of hepatic steatosis. In patients with frequent exacerbations, there is a significant positive correlation between leptin levels and TNF-a factor, which may be associated with an increase in overall inflammation. The revealed imbalance of adiponectin and leptin content in patients with COPD with overweight is a factor in the progression of NAFLD.

THE EFFECTIVENESS OF COMPLEX THERAPY WITH THE INCLUSION OF THE URSODEOXYCHOLIC ACID IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

2021 ◽  
Vol 74 (10) ◽  
pp. 2575-2579
Author(s):  
Iryna O. Khramtsova ◽  
Maria A. Derbak ◽  
Taras M. Ganich ◽  
Oleksandr O. Boldizhar ◽  
Yana V. Lazur
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Liver Disease ◽  
Fatty Liver ◽  
Standard Therapy ◽  
Fatty Liver Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Alcoholic Fatty Liver ◽  
Positive Effect ◽  
Alcoholic Fatty Liver Disease

The aim: Was increase the effectiveness of treatment in patients with non-alcoholic fatty liver disease (NAFLD) comorbid with chronic obstructive pulmonary disease (COPD) by using ursodeoxycholic acid (UDCA) in combination with ademethionine. Materials and methods: Under observation was 98 patients with a diagnosis of NAFLD and COPD group II or their combination. Patients were divided into 3 groups: 1 (n = 36) – COPD + NASH – in addition to standard COPD therapy received UDCA 15 mg / kg / day – 6 months and ademethionine 1000 mg IV once a day for 10 days, followed by oral administration of 500 mg 2 times per day – 20 days, and group 2 (n = 32) – COPD + hepatic steatosis – in addition to standard therapy – UDCA 15 mg / kg / day – 6 months. Group 3 (n = 30) – COPD received standard therapy for COPD. Results: UDCA with ademethionine on the background of standard COPD therapy reduces the clinical manifestations of NAFLD and normalizes liver function. The combination of UDCA with ademethionine not only has a positive effect on the course of NAFLD, but also reduces the intensity of dyspnea, systemic inflammation, improves the external respiration function and reduces anxiety and depression. Patients receiving UDCA + ademethionine for 6 months of follow-up had no exacerbations of COPD. Conclusions: UDCA in combination with ademethionine in COPD courses have a positive effect on the course of NAFLD, and also reduces the intensity of dyspnea, improves the external respiratory function and reduces the frequency of COPD hospitalization.

scholarly journals Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease

2017 ◽  
Vol 49 (6) ◽  
pp. 1601923 ◽  
Author(s):  
Damien Viglino ◽  
Ingrid Jullian-Desayes ◽  
Mélanie Minoves ◽  
Judith Aron-Wisnewsky ◽  
Vincent Leroy ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Pulmonary Disease ◽  
Liver Damage ◽  
Fatty Liver Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Nonalcoholic Fatty Liver

Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and mortality. Low-grade inflammation, oxidative stress and ectopic fat, common features of chronic obstructive pulmonary disease (COPD), might contribute to the development of NAFLD.We aimed to investigate the prevalence of NAFLD and to evaluate the relationship between various types of liver damage and COPD severity, comorbidities and circulating inflammatory cytokines. Validated noninvasive tests (FibroMax: SteatoTest, NashTest and FibroTest) were used to assess steatosis, nonalcoholic steatohepatitis (NASH) and liver fibrosis. Patients underwent an objective assessment of COPD comorbidities, including sleep studies. Biological parameters included a complete lipid profile and inflammatory markers.In COPD patients the prevalence of steatosis, NASH and fibrosis were 41.4%, 36.9% and 61.3%, respectively. In multivariate analysis, SteatoTest and FibroTest were significantly associated with sex, body mass index (BMI), untreated sleep apnoea and insulin resistance, and, in addition, COPD Global Initiative for Chronic Obstructive Lung Disease stage for SteatoTest. Patients with steatosis had higher tumour necrosis factor-α levels and those with NASH or a combination of liver damage types had raised leptin levels after adjustment for age, sex and BMI.We concluded that NAFLD is highly prevalent in COPD and might contribute to cardiometabolic comorbidities.

scholarly journals Markers of Immune Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Combination with Chronic Obstructive Pulmonary Disease

2021 ◽  
Vol 6 (4) ◽  
pp. 119-125
Author(s):  
I. O. Khramtsova ◽  
◽  
M. A. Derbak
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Pulmonary Disease ◽  
Neutrophil Elastase ◽  
Fatty Liver Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Nonalcoholic Fatty Liver

The purpose of the study was to determine markers of immune inflammation in patients with nonalcoholic fatty liver disease combined with chronic obstructive pulmonary disease. Materials and methods. The observation revealed 82 patients who were treated in the pulmonology and gastroenterology department of the Andriy Novak Transcarpathian Regional Clinical Hospital during 2018-2020 with a diagnosis of nonalcoholic fatty liver disease and chronic obstructive pulmonary disease II group B and C. Among the examined there were 61.0% (50) men and 40.0% (32) women. The average age was 57.8±1.5 years old. Results and discussion. As a result of the conducted research it is established that increased levels of chronic immune inflammation markers were observed in all examined with significant increase in patients with a comorbid condition. The highest concentrations of C-reactive protein were found in patients with nonalcoholic fatty liver disease combined with chronic obstructive pulmonary disease with frequent exacerbations and hospitalization, and exceeded the normal values by 8.3 times. The levels of tumor necrosis factor-α and neopterin in patients with frequent exacerbations of chronic obstructive pulmonary disease and hospitalization were by 2.7 times and 1.9 times higher than in patients with a small number of exacerbations and by 3.2 and 3.9 times higher than in patients with nonalcoholic fatty liver disease without chronic obstructive pulmonary disease. The indexes of interleukin-6, transforming growth factor-β, the number of IgG antibodies to neutrophil elastase and the level of tissue inhibitor of matrix proteinases-1 remain consistently high in all patients with combined pathology of nonalcoholic fatty liver disease and chronic obstructive pulmonary disease regardless of the frequency of exacerbations, thus supporting inflammation even in remission. Elastase antibody levels correlate directly with the levels of the tissue metalloproteinase-1 inhibitor and increase with the degree of severety of fibrosis, which may indicate a high level of serum neutrophil elastase activity in patients with nonalcoholic fatty liver disease in combination with chronic obstructive pulmonary disease and its participation in fibrosis. Conclusion. Patients with nonalcoholic fatty liver disease in combination with chronic obstructive pulmonary disease showed an increased level of chronic systemic inflammation of low intensity based on the analysis of C-reactive protein, tumor necrosis factor-α, neopterin and interleukin-6 compared with nonalcoholic fatty liver disease without chronic obstructive pulmonary disease even in remission, which indicates an aggravating course of the disease in combination of two pathologies. Stably high concentration of IgG antibodies to neutrophil elastase may indirectly indicate the maintenance of the activity of this enzyme in the serum of patients with nonalcoholic fatty liver disease in chronic obstructive pulmonary disease and confirms its participation in liver fibrogenesis

scholarly journals Molecular Mechanisms of Lipid Metabolism Disorders in Infectious Exacerbations of Chronic Obstructive Pulmonary Disease

2021 ◽  
Vol 22 (14) ◽  
pp. 7634
Author(s):  
Stanislav Kotlyarov ◽  
Anna Kotlyarova
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lipid Metabolism ◽  
Pulmonary Disease ◽  
Plasma Membranes ◽  
Molecular Mechanisms ◽  
Bacterial Colonization ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Copd Exacerbations ◽  
Lipid Metabolism Disorders

Exacerbations largely determine the character of the progression and prognosis of chronic obstructive pulmonary disease (COPD). Exacerbations are connected with changes in the microbiological landscape in the bronchi due to a violation of their immune homeostasis. Many metabolic and immune processes involved in COPD progression are associated with bacterial colonization of the bronchi. The objective of this review is the analysis of the molecular mechanisms of lipid metabolism and immune response disorders in the lungs in COPD exacerbations. The complex role of lipid metabolism disorders in the pathogenesis of some infections is only beginning to be understood, however, there are already fewer and fewer doubts even now about its significance both in the pathogenesis of infectious exacerbations of COPD and in general in the progression of the disease. It is shown that the lipid rafts of the plasma membranes of cells are involved in many processes related to the detection of pathogens, signal transduction, the penetration of pathogens into the cell. Smoking disrupts the normally proceeded processes of lipid metabolism in the lungs, which is a part of the COPD pathogenesis.

Use of chloride-bicarbonate sodium mineral water ‘Karachinskaya’ in patients with non-alcoholic fatty liver disease

2019 ◽  
Vol 1 (6) ◽  
pp. 47-52
Author(s):  
A. B. Krivosheev ◽  
A. D. Kuimov ◽  
T. A. Tuguleva
Keyword(s):  
Lipid Metabolism ◽  
Liver Disease ◽  
Fatty Liver ◽  
Total Cholesterol ◽  
Fatty Liver Disease ◽  
Mineral Water ◽  
Atherogenic Index ◽  
Alcoholic Fatty Liver ◽  
Lipid Metabolism Disorders ◽  
Alcoholic Fatty Liver Disease

The aim of the study was to determine for patients with non-alcoholic fatty liver disease (NAFLD) the possibilities and effectiveness of the course use of chloride-bicarbonate sodium mineral water (MW) (by the example of MW Karachinskaya). A total of 76 patients (20 women and 56 men) with NAFLD aged 42 to 72 years (mean age 59.4 ± 1.2 years) were examined. MV was taken in 200 ml in 8, 10, 12, 15 and 17 hours (5 times a day, in a volume of 1,000 ml), room temperature (18-20 °C). The course of treatment was 10 days. In the dynamics of treatment, lipid spectrum parameters were evaluated: total cholesterol, triglycerides, high, low and very low density lipoprotein cholesterol, atherogenic index. The results obtained allow us to draw the following conclusions. 1. In patients with NAFLD observed by us, comorbid pathology is observed at least 3-4 diseases of internal organs are registered at the same time. The most frequently detected pathology of the cardiovascular system and disorders of carbohydrate metabolism. 2. The vast majority of patients revealed lipid metabolism disorders. The most significant disorders were characterized by increased levels of total cholesterol. 3. The inclusion of the 10-day drinking course of the chloride-bicarbonate sodium MW Karachinskaya’ contributes to the correction of lipid metabolism. The identified cholesterol-lowering effect of MW Karachinskaya' with mild and moderate hypercholesterolemia allows recommending it for non-pharmacological correction of elevated total cholesterol, which is currently considered as an established risk factor for IHD and arterial hypertension.

Sign in / Sign up

Export Citation Format

Share Document